A multiplexed in vivo approach to identify driver genes in small cell lung cancer

一种用于鉴定小细胞肺癌驱动基因的多重体内方法

阅读:5
作者:Myung Chang Lee ,Hongchen Cai ,Christopher W Murray ,Chuan Li ,Yan Ting Shue ,Laura Andrejka ,Andy L He ,Alessandra M E Holzem ,Alexandros P Drainas ,Julie H Ko ,Garry L Coles ,Christina Kong ,Shirley Zhu ,ChunFang Zhu ,Jason Wang ,Matt van de Rijn ,Dmitri A Petrov ,Monte M Winslow ,Julien Sage

Abstract

Small cell lung cancer (SCLC) is a lethal form of lung cancer. Here, we develop a quantitative multiplexed approach on the basis of lentiviral barcoding with somatic CRISPR-Cas9-mediated genome editing to functionally investigate candidate regulators of tumor initiation and growth in genetically engineered mouse models of SCLC. We found that naphthalene pre-treatment enhances lentiviral vector-mediated SCLC initiation, enabling high multiplicity of tumor clones for analysis through high-throughput sequencing methods. Candidate drivers of SCLC identified from a meta-analysis across multiple human SCLC genomic datasets were tested using this approach, which defines both positive and detrimental impacts of inactivating 40 genes across candidate pathways on SCLC development. This analysis and subsequent validation in human SCLC cells establish TSC1 in the PI3K-AKT-mTOR pathway as a robust tumor suppressor in SCLC. This approach should illuminate drivers of SCLC, facilitate the development of precision therapies for defined SCLC genotypes, and identify therapeutic targets. Keywords: CP: Cancer; CRISPR screening; MTOR; SCLC; TSC1; functional genomics; meta-analysis; mouse models; naphthalene; small cell lung cancer; tumor suppression.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。